Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Equities research analysts at Svb Leerink issued their Q2 2019 earnings per share estimates for shares of Vertex Pharmaceuticals in a report released on Wednesday, May 1st, according to Zacks Investment Research. Svb Leerink analyst G. Porges anticipates that the pharmaceutical company will earn $0.71 per share for the quarter. Svb Leerink has a “Market Perform” rating on the stock. Svb Leerink also issued estimates for Vertex Pharmaceuticals’ Q3 2019 earnings at $0.70 EPS, Q4 2019 earnings at $0.72 EPS and FY2019 earnings at $2.94 EPS.
Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Tuesday, April 30th. The pharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.49. Vertex Pharmaceuticals had a return on equity of 22.63% and a net margin of 66.01%. The firm had revenue of $857.00 million during the quarter, compared to analyst estimates of $853.00 million. During the same quarter in the prior year, the company earned $0.76 EPS. The business’s revenue was up 34.3% compared to the same quarter last year.
Several other research analysts have also issued reports on the company. Credit Suisse Group assumed coverage on Vertex Pharmaceuticals in a research report on Monday. They issued an “outperform” rating and a $209.00 target price for the company. BidaskClub lowered Vertex Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, May 14th. ValuEngine raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, May 1st. Needham & Company LLC restated a “buy” rating and issued a $195.00 price target on shares of Vertex Pharmaceuticals in a research note on Wednesday, May 1st. Finally, JPMorgan Chase & Co. restated a “buy” rating and issued a $209.00 price target on shares of Vertex Pharmaceuticals in a research note on Wednesday, May 1st. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and sixteen have assigned a buy rating to the company’s stock. Vertex Pharmaceuticals has an average rating of “Buy” and a consensus price target of $203.62.
Shares of NASDAQ:VRTX traded up $3.39 during trading on Monday, hitting $169.12. The stock had a trading volume of 669,821 shares, compared to its average volume of 1,384,889. Vertex Pharmaceuticals has a 12 month low of $144.07 and a 12 month high of $195.81. The firm has a market capitalization of $43.22 billion, a P/E ratio of 59.76, a P/E/G ratio of 2.45 and a beta of 1.56. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.66 and a current ratio of 3.78.
Institutional investors and hedge funds have recently modified their holdings of the business. RMB Capital Management LLC boosted its stake in Vertex Pharmaceuticals by 3.0% during the 4th quarter. RMB Capital Management LLC now owns 21,113 shares of the pharmaceutical company’s stock valued at $3,499,000 after purchasing an additional 617 shares during the last quarter. Eastern Bank lifted its holdings in shares of Vertex Pharmaceuticals by 43.2% during the 4th quarter. Eastern Bank now owns 3,315 shares of the pharmaceutical company’s stock valued at $549,000 after buying an additional 1,000 shares during the period. State Treasurer State of Michigan lifted its holdings in shares of Vertex Pharmaceuticals by 74.8% during the 4th quarter. State Treasurer State of Michigan now owns 133,168 shares of the pharmaceutical company’s stock valued at $22,067,000 after buying an additional 57,000 shares during the period. HighPoint Advisor Group LLC lifted its holdings in shares of Vertex Pharmaceuticals by 3.2% during the 4th quarter. HighPoint Advisor Group LLC now owns 5,097 shares of the pharmaceutical company’s stock valued at $952,000 after buying an additional 160 shares during the period. Finally, Biondo Investment Advisors LLC lifted its holdings in shares of Vertex Pharmaceuticals by 8.8% during the 4th quarter. Biondo Investment Advisors LLC now owns 46,020 shares of the pharmaceutical company’s stock valued at $7,626,000 after buying an additional 3,715 shares during the period. Institutional investors and hedge funds own 94.92% of the company’s stock.
In other Vertex Pharmaceuticals news, SVP Paul M. Silva sold 161 shares of the stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $165.41, for a total transaction of $26,631.01. Following the sale, the senior vice president now directly owns 17,759 shares in the company, valued at approximately $2,937,516.19. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Stuart A. Arbuckle sold 5,624 shares of the stock in a transaction on Monday, April 15th. The shares were sold at an average price of $181.75, for a total value of $1,022,162.00. Following the sale, the executive vice president now owns 36,272 shares in the company, valued at $6,592,436. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 51,247 shares of company stock worth $8,998,147. Company insiders own 0.70% of the company’s stock.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.